Abstract
In the United States, herpes zoster (HZ) and related complications are estimated to result in approximately $1.3 billion in medical care costs and $1.7 billion in indirect costs annually. In this study, we compared the cost-effectiveness of a new Adjuvanted Recombinant Zoster Vaccine (RZV), containing recombinant varicella-zoster virus glycoprotein E and the AS01B Adjuvant System, versus No Vaccine, as well as versus the live attenuated HZ vaccine (Zoster Vaccine Live (ZVL)) in subjects aged 60+ years of age (YOA) and other age cohorts aged 50+ YOA. A multi-cohort Markov model was developed which follows 1 million individuals over their remaining lifetimes from the year of vaccination with annual cycle lengths. Second dose compliance for RZV was assumed to be 69%. Efficacy and waning parameters were derived from clinical trials for both vaccines. Epidemiological parameters, costs and utility model inputs were derived from US-specific population-based data. Costs and outcomes were discounted at 3% per year. Deterministic and probabilistic sensitivity analysis, along with scenario and threshold analysis were carried out to explore the overall uncertainty in the model. The model estimated that, compared to No Vaccine against HZ, R...Continue Reading
Citations
Nov 7, 2018·JAMA Internal Medicine·Phuc Le, Michael B Rothberg
Nov 7, 2018·JAMA Internal Medicine·Desmond CurranPhilip Buck
Jan 10, 2019·Human Vaccines & Immunotherapeutics·Desmond CurranBarbara P Yawn
Feb 19, 2019·Annals of Internal Medicine·Lisa A ProsserKathleen Dooling
Jun 13, 2020·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·Kenneth E SchmaderDesmond Curran
Jul 11, 2019·Open Forum Infectious Diseases·Christopher F CarpenterDavid Hutton
Apr 1, 2019·Dermatology and Therapy·Makoto ShiragamiDaisuke Watanabe
Jun 30, 2019·Applied Health Economics and Health Policy·Ashleigh McGirrDesmond Curran
Oct 30, 2018·Drugs & Aging·Yahiya Y Syed
Aug 24, 2019·Human Vaccines & Immunotherapeutics·Antonio VolpiElisabetta Franco
Dec 7, 2018·BMC Medicine·Pieter T de BoerMaarten J Postma
Aug 8, 2020·Human Vaccines & Immunotherapeutics·Sandra E TalbirdCosmina S Hogea
Sep 12, 2020·Pain and Therapy·Xin-Xing WangBi-Fa Fan
Oct 13, 2020·Journal of Managed Care & Specialty Pharmacy·Brandon J PattersonHung-Fu Tseng
Jan 7, 2021·Journal of Market Access & Health Policy·Mohamed Neine, Desmond Curran
Feb 25, 2021·BMJ Open·James F MbintaColin R Simpson
Jul 2, 2021·Mayo Clinic Proceedings. Innovations, Quality & Outcomes·Brandon J PattersonJeffrey J Stoddard
Aug 3, 2021·Vaccine·Justin CarricoCosmina Hogea
Aug 6, 2021·Vaccine·Andrew J LeidnerYuping Tsai
Aug 7, 2021·Human Vaccines & Immunotherapeutics·Qiang WangLeesa Lin
Aug 21, 2021·Medicine·Shih-Wei LaiBing-Fang Hwang
Nov 2, 2021·JAMA Internal Medicine·Ravi GoudRichard A Forshee
Nov 19, 2021·Journal of Medical Economics·Sariya UdayachalermNathorn Chaiyakunapruk
Dec 8, 2021·Infectious Diseases and Therapy·Desmond CurranBarbara P Yawn
Jan 21, 2022·Human Vaccines & Immunotherapeutics·Desmond CurranSara Poston